Biosimilars Industry Global Market Trends, Share, Size and 2021 Global Biosimilars Market and Forecast to 2021 | Page 2

Biosimilars Industry Global Market Analysis, Growth, Share, Industry Trends
and Forecasts to 2021
The biosimilars are poised to capture an unprecedented position in the biopharmaceutical industry driven
by an increased extent of adoption and growing investment and deal making activity globally. The global
biosimilars market is predicted to cross US$ 25 Billion mark by 2020. With the continuous increasing
demand for biologics, manufacturers are looking for novel strategies that will help them attain maximum
returns on investment. Biosimilars are seen as the key weapon to curbing soaring healthcare costs globally.
The major factor that is driving the market for biosimilars industry is the fact that major biologics are
nearing the patent cliff. Further, the lower cost of these drugs as compared to the patented biologics, the
increasing encumbrance to curb healthcare costs globally, increasing nationwide government initiatives,
and the strong pipeline for the biosimilar drugs is expected to fuel the biosimilars industry.
Key Highlights of the Report:
Biosimilars Market - By Product Type:
The erythropoietin (EPO) captures maximum share of the global biosmilars market.
The Granulocyte- Colony Stimulating Factor (G-CSF) market is expected to cross US$ 6 Billion mark by 2021.
The Human Growth Hormone (HGH) biosimilars market is expected to grow with a double digit CAGR
during the period 2016 - 2021.
The monoclonal antibody is expected to show the highest growth rate during the period 2016 - 2021.
The insulin and interferon product segment each accounted for single digit share of the global biosimilars
market respectively in 2015.
Complete report available at http://www.marketreportsonline.com/504244.html